Cargando…

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous clonal disease associated with unmet medical needs. Paralleling the pathology of other cancers, AML tumorigenesis and propagation can be ascribed to dysregulated cellular processes, including apoptosis. This function and othe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Douglas D., Tang, Qiuqiong, Kong, Yanhui, Rong, Tao, Wang, Qixin, Li, Na, Fang, Xu, Gu, Jiaxing, Xiong, Dengkun, Yin, Yan, Deng, Jing, Yang, Dajun, Zhai, Yifan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093284/ https://www.ncbi.nlm.nih.gov/pubmed/33941774 http://dx.doi.org/10.1038/s41420-021-00465-5

Ejemplares similares

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
por: Fang, Douglas D., et al.
Publicado: (2021)

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
por: Fang, Douglas D., et al.
Publicado: (2022)

A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
por: Yi, Hanjie, et al.
Publicado: (2018)

Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells
por: Chen, Haibo, et al.
Publicado: (2017)

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
por: Luo, Qiuyun, et al.
Publicado: (2020)

Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
por: Aguilar, Angelo, et al.
Publicado: (2017)

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma
por: Chen, Zide, et al.
Publicado: (2018)

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
por: Legler, Karen, et al.
Publicado: (2018)

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma
por: Zhang, Peng, et al.
Publicado: (2023)

Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
por: Bivol, Svetlana, et al.
Publicado: (2022)

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
por: Liu, Xuechao, et al.
Publicado: (2019)

The natural compound gracillin exerts potent antitumor activity by targeting mitochondrial complex II
por: Min, Hye-Young, et al.
Publicado: (2019)

Juglone exerts antitumor effect in ovarian cancer cells
por: Fang, Fang, et al.
Publicado: (2015)

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair
por: Zhou, Jianli, et al.
Publicado: (2023)

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer
por: Wu, Meng, et al.
Publicado: (2022)

Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin’s lymphoma models and in cells deficient in DNA damage repair
por: Zhou, Jianli, et al.
Publicado: (2023)

Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities
por: Sawaguchi, Yuichi, et al.
Publicado: (2021)

Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts
por: Fang, Bin, et al.
Publicado: (2020)

XWL-1-48 exerts antitumor activity via targeting topoisomerase II and enhancing degradation of Mdm2 in human hepatocellular carcinoma
por: Wang, Yajie, et al.
Publicado: (2017)

Tor-Mediated Induction of Autophagy via an Apg1 Protein Kinase Complex
por: Kamada, Yoshiaki, et al.
Publicado: (2000)

Formation Process of Autophagosome Is Traced with Apg8/Aut7p in Yeast
por: Kirisako, Takayoshi, et al.
Publicado: (1999)

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
por: Al-Sudani, Hussein, et al.
Publicado: (2023)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma
por: Liu, Xu-Jie, et al.
Publicado: (2017)

Dissection of Autophagosome Formation Using Apg5-Deficient Mouse Embryonic Stem Cells
por: Mizushima, Noboru, et al.
Publicado: (2001)

Regulation of tight junction assembly and epithelial morphogenesis by the heat shock protein Apg-2
por: Aijaz, Saima, et al.
Publicado: (2007)

Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro
por: Merz, Christian, et al.
Publicado: (2015)

Wetting Mechanism and Experimental Study of Synergistic Wetting of Bituminous Coal with SDS and APG1214
por: Sun, Liying, et al.
Publicado: (2021)

Artificial Macrocycles as Potent p53–MDM2 Inhibitors
por: Estrada-Ortiz, Natalia, et al.
Publicado: (2017)

Association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and retinoblastoma susceptibility
por: Cao, Qixin, et al.
Publicado: (2018)

Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis
por: Chen, Linying, et al.
Publicado: (2019)

Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
por: Oya, Kazumasa, et al.
Publicado: (2021)

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
por: Saiki, Anne Y., et al.
Publicado: (2014)

DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
por: Yamato, Michiko, et al.
Publicado: (2022)

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
por: Lu, Lei, et al.
Publicado: (2014)

Augmented antitumor activity of 5‐fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells
por: Imanishi, Mamiko, et al.
Publicado: (2019)

APG: an Active Protein-Gene Network Model to Quantify Regulatory Signals in Complex Biological Systems
por: Wang, Jiguang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v3bitd7lglnuq9i3qipnadh49l